Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients

Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Carl Neuberg Str 1, Hannover 30625, Germany.
British Journal of Cancer (Impact Factor: 4.82). 05/2005; 92(10):1862-8. DOI: 10.1038/sj.bjc.6602590
Source: PubMed

ABSTRACT Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. However, treatment options are limited and often inefficient. The aim of this study was to determine current survival rates for patients diagnosed with HCC and to identify prognostic factors, which will help in choosing optimal therapies for individual patients. A retrospective analysis of medical records was performed on 389 patients who were identified through the central tumour registry at our institution from 1998 to 2003. Clinical parameters, treatments received and survival curves from time of diagnosis were analysed. Overall median survival was 11 months. Liver cirrhosis was diagnosed in 80.5% of all patients. A total of 170 patients received transarterial chemoembolisation (TACE) and/or percutaneous ethanol injections (PEI) with a median survival rate of 16 months for patients receiving TACE, 11 months for patients receiving PEI and 24 months for patients receiving TACE followed by PEI. Independent negative prognostic parameters for survival were the presence of portal vein thrombosis, advanced liver cirrhosis (Child-Pugh score B or C) and a score of >2. This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received.

Download full-text


Available from: Frank Papendorf, Apr 14, 2015
  • Source
    • "Current treatment options for patients with HCC include surgical resection, orthotopic liver transplantation, transarterial chemoembolization (TACE) and local ablative therapies such as percutaneous ethanol injection and radiofrequency ablation [6]. However, up to 50% of patients are diagnosed with such advanced disease that none of these treatment options are available for them [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with increasing incidence in the Western World. In contrast to most other malignancies, only surgical and local ablative therapeutic options have shown efficacy in patients with HCC. Systemic chemotherapy has failed to show a substantial benefit for these patients. Therefore, a number of immunotherapeutic trials have been performed to evaluate the efficacy of immunotherapy for the treatment of HCC. Although only a limited number of patients have been enrolled in most trials so far, results from these studies clearly suggest that immunotherapy is safe in HCC patients. Here, we review recent immunotherapy trials in HCC.
    Reviews on Recent Clinical Trials 02/2008; 3(1):31-9. DOI:10.2174/157488708783330549
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To present current data on technique, indications and results of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). The principle of TACE is the intra-arterial injection of chemotherapeutic drug combinations like doxoru- bicin, cisplatin and mitomycin into the hepatic ar- tery, followed by lipiodol injection, Gelfoam for vessel occlusion and degradable microspheres. The side effects and complications after TACE range from fever, upper abdominal pain and vo- miting to acute or chronic liver cell failure. The palliative effect in unresectable HCC using TACE allows local tumor control in 15 to 60 % of cases and 5-year survival rates ranging from 8 - 43 %. The potentially curative treatment option allows local tumor control from 18 - 63 %. The neoadju- vant treatment option of TACE in combination with other treatment options like percutaneous ethanol injection (PEI) or radiofrequency ablation (RFA) reach local tumor control rates between 80 - 96 %. The bridging effect of TACE before liver transplantation reaches 5-year survival rates from 59 - 93 %. The symptomatic therapy option of TACE is used to counteract pain directly caused by HCC and acute/subacute bleeding in the HCC. The local tumor response reaches up to 88 % and the bleed- ing control is from 83 to 100 %. Conclusion: TACE is a potentially curative, pal- liative, neoadjuvant, bridging and symptomatic therapy option for local and diffuse HCC.
Show more